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Abstract
Background: Probiotics are live microorganisms that may confer health benefits when ingested. Randomized trials
suggest that probiotics significantly decrease the incidence of ventilator-associated pneumonia (VAP) and the overall
incidence of infection in critically ill patients. However, these studies are small, largely single-center, and at risk of bias.
The aim of the PROSPECT pilot trial was to determine the feasibility of conducting a larger trial of probiotics to prevent
VAP in mechanically ventilated patients in the intensive care unit (ICU).
Methods: In a randomized blinded trial, patients expected to be mechanically ventilated for ≥72 hours were allocated
to receive either 1 × 1010 colony-forming units of Lactobacillus rhamnosus GG or placebo, twice daily. Patients were
excluded if they were at increased risk of L. rhamnosus GG infection or had contraindications to enteral medication.
Feasibility objectives were: (1) timely recruitment; (2) maximal protocol adherence; (3) minimal contamination; and (4)
estimated VAP rate ≥10 %. We also measured other infections, diarrhea, ICU and hospital length of stay, and mortality.
Results: Overall, in 14 centers in Canada and the USA, all feasibility goals were met: (1) 150 patients were randomized
in 1 year; (2) protocol adherence was 97 %; (3) no patients received open-label probiotics; and (4) the VAP rate was
19 %. Other infections included: bloodstream infection (19.3 %), urinary tract infections (12.7 %), and skin and soft tissue
infections (4.0 %). Diarrhea, defined as Bristol type 6 or 7 stools, occurred in 133 (88.7 %) of patients, the median length
of stay in ICU was 12 days (quartile 1 to quartile 3, 7–18 days), and in hospital was 26 days (quartile 1 to quartile 3,
14–44 days); 23 patients (15.3 %) died in the ICU.
Conclusions: The PROSPECT pilot trial supports the feasibility of a larger trial to investigate the effect of L. rhamnosus
GG on VAP and other nosocomial infections in critically ill patients.
Trial registration: Clinicaltrials.gov NCT01782755. Registered on 29 January 2013.
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Background
Probiotics are live microorganisms that may have health
benefits when ingested [1]. Probiotics have been studied
in randomized controlled trials in a variety of conditions
in the community and hospital setting [2–5]. In the inten-
sive care unit (ICU), probiotics have been studied for the
prevention of ventilator-associated pneumonia (VAP),
potentially by enhancing intestinal barrier function and
reducing the load of pathogenic bacteria [6, 7]. As the
commonest nosocomial infection in the ICU, VAP is asso-
ciated with a two-fold attributable risk of death, and an
attributable cost of US$ 10,000–13,000 per patient [8].
A recent meta-analysis of 23 randomized controlled
trials suggested that administering probiotics to critically
ill mechanically ventilated patients is associated with a
25 % reduction in the incidence of VAP and an 18 % re-
duction in the incidence of all nosocomial infections [9].
A subsequent Cochrane review [10] of eight randomized
controlled trials that enrolled 1083 patients in total and
compared various single or combined probiotics to a
control intervention (placebo, glutamine, fermentable
fibre, peptide, chlorhexidine) suggested that probiotics
might significantly decrease the incidence of VAP (odds
ratio, 0.70; 95 % confidence interval, 0.52–0.95). One
high-quality randomized controlled trial compared a
combination of oropharyngeal plus gastric Lactobacillus
rhamnosus GG with placebo in 146 patients who were
expected to remain intubated for at least 72 hours [11],
and found that those who received L. rhamnosus GG had
lower rates of VAP (relative risk, 0.46; 95 % confidence
interval, 0.26–0.82). The three randomized controlled tri-
als that reported diarrhea as an outcome found a trend to-
ward a lower incidence with probiotics (odds ratio, 0.72;
95 % confidence interval, 0.47–1.09; very low quality evi-
dence); however Clostridium difficile was not analyzed.
There were no reports of nosocomial infections caused by
the probiotic organisms in these trials. Although promising,
these small (n = 50–300), mostly single-center randomized
controlled trials generate results that have uncertain in-
ternal and external validity. Therefore, while promising,
current knowledge does not provide sufficient evidence to
draw firm conclusions about the efficacy and safety of pro-
biotics for the prevention of VAP in the ICU [10].
In the context of a research program on probiotics in
critical illness (Fig. 1), we conducted a pilot trial to evalu-
ate the feasibility of a large randomized controlled trials in
critically ill patients, investigating whether orally ingested
L. rhamnosus GG prevents VAP and other nosocomial in-
fections (Probiotics: Prevention of Severe Pneumonia and
Endotracheal Colonization Pilot Trial, the PROSPECT
pilot trial; NCT01782755). The criteria for feasibility were
successful and timely pilot trial recruitment, high adher-
ence to protocol, minimal open-label use of probiotics,
and a VAP incidence of at least 10 %. We also report the
results of three substudies nested within this pilot trial.
Methods
Study design
We conducted a randomized concealed blinded parallel
group trial in 14 ICUs in Canada and the USA, in which
patients were allocated to placebo or probiotic in a fixed
allocation ratio of 1:1 using the randomize.net website.
Randomization was stratified by ICU and by medical,
surgical, or trauma status, in variable unspecified block
sizes. Further details are reported in the protocol manu-
script [12].
We included patients ≥18 years of age who were ex-
pected to be mechanically ventilated ≥72 hours. We ex-
cluded patients who: (a) had been mechanically
ventilated for more than 72 hours at the time of screen-
ing, (b) were immunocompromised (HIV <200 CD4
cells/μl, chronic immunosuppressive medications, prior
Fig. 1 The probiotics in ICU research program. The PROSPECT pilot trial is part of the probiotics in ICU Research Program
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organ or hematological transplant, absolute neutrophil
count <500 cells/μl), (c) had an increased risk of endo-
vascular infection (history of rheumatic heart disease,
congenital heart defect, mechanical valve, endocarditis,
endovascular graft, or permanent endovascular device,
such as hemodialysis catheter, pacemaker, or defibrillator),
(d) had gastroesophageal or intestinal injury or recent sur-
gery of the esophagus, stomach, bowel, hepatobiliary tree,
spleen, or pancreas in the previous 72 hours, suspected or
documented bowel ischemia, and severe acute pancreatitis
(pancreatitis with any organ dysfunction), (e) had strict
contraindication or inability to receive enteral medica-
tions, (f) were pregnant, (g) were undergoing withdrawal
of life support, and (h) were enrolled in this or an ongoing
related trial.
After written informed a-priori consent was obtained
from the patient or the patient’s substitute decision
maker, the local study pharmacist obtained the allocation
from www.randomize.net.
Trial interventions
Patients allocated to the intervention received 1 × 1010
colony-forming units of L. rhamnosus GG (Culturelle,
Locin Industries, Ltd) in one capsule suspended in tap
water, administered via gastric or duodenal tube twice
daily while in the ICU. Patients allocated to placebo re-
ceived microcrystalline cellulose suspended in tap water,
identical in appearance and consistency to the probiotic,
and administered similarly. Identical placebo ensured
blinding of all possible parties (patient, family, clinicians,
laboratory, and research personnel, including the biostat-
istician). The probiotic and placebo were prepared by
the manufacturer of L. rhamnosus GG, Culturelle, as
used in a recent trial [11]. Patients received the study
product until discharge from ICU (administered in
capsule form or as a suspension if no feeding tube was
in place), on isolation of Lactobacillus species from a
sterile site or reported as the sole or predominant organ-
ism in a culture from a non-sterile site, or 60 days after
randomization.
All other management, including VAP prevention
strategies, was at the discretion of the ICU team and ac-
cording to local practice.
Feasibility outcomes
The four feasibility outcomes were: (a) successful recruit-
ment, defined as ≥2 patients per month on average per
site (total 150 from all study sites) over 1 year, (b) adher-
ence to protocol, defined as ≥90 % of the prescribed inter-
vention being administered during the ICU stay, (c)
minimal contamination, defined as ≤5 % of patients re-
ceiving open-label probiotic, in either group, during the
ICU stay, and (d) a VAP incidence of ≥10 % as defined by
the Centers for Disease Control and Prevention [13].
Clinical outcome measures
Clinical outcome measures used in this pilot were those
we will record in the main PROSPECT trial and in-
cluded: the primary outcome measure, VAP; other ICU-
acquired infections, defined using an adaptation of the
International Sepsis Forum Consensus Conference on
Definitions of Infections in the ICU [14]; diarrhea (de-
fined as either ≥3 stools/day [15] or ≥1 Bristol type 6 or
7 stool, where type 6 is described as mushy stool, and
type 7 is described as entirely liquid [16]), antibiotic-
associated diarrhea (defined as ≥3 stools/day occurring
within 24 hours of antibiotics) [17] and C. difficile (de-
fined as three or more episodes of unformed stools in
24 hours and C. difficile toxin positive stool), or colono-
scopic or histopathologic findings of pseudomembran-
ous colitis; C. difficile was the only clinical outcome
tracked after patients’ ICU stay [18]. We also measured
duration of mechanical ventilation; ICU and hospital
stay; and ICU and hospital mortality.
Antimicrobial administration
Antimicrobial therapy was recorded prospectively daily
in each patient, and we calculated days of therapy as well
as antimicrobial-free days in ICU.
Follow-up
Patients were reviewed daily by the research coordinator
in each ICU to collect baseline data (e.g., demographics,
illness severity, advanced life support), daily data (e.g.,
study intervention administration and reasons for not
administering, relevant medications including antimicro-
bials and prokinetics, VAP prevention co-interventions,
culture results, clinical diagnoses, length of stay, mortal-
ity), and methods center data (e.g., infection adjudication
forms). Research coordinators submitted relevant clin-
ical, radiologic, and microbiologic data from patients
who had clinically suspected VAP to the methods center.
All other ICU-acquired infections were also documented
and source data were collected. Any Lactobacillus spe-
cies identified in a sterile site or cultured as the sole or
predominant organism in a non-sterile site prompted
discontinuation of the study product. Any reasons for
protocol non-compliance were recorded daily while in
ICU, along with contamination by probiotic adminis-
tered outside the study protocol.
Serious adverse events
A serious adverse event is defined as any adverse occur-
rence or event, or response to a drug or intervention,
whether expected or not; that requires in-patient
hospitalization or prolongation of existing hospitalization;
that results in persistent or significant disability or incap-
acity; or is a congenital anomaly or birth defect; that is life
threatening or results in death [19]. Serious adverse events
Cook et al. Trials  (2016) 17:377 Page 3 of 10
were reported and documented in accordance with our
guidelines for academic critical care trials of common in-
terventions [20].
Substudy no. 1: PROSPECT-TIMES
We conducted a multicenter time-in-motion study
(PROSPECT-TIMES, Probiotics to prevent Severe Pneu-
monia and Endotracheal Colonization Trial—Time-In-
Motion Evaluation Study) to document and describe the
time and activities of the Research Coordinators who
followed their first 10 randomized patients, concurrently
documenting trial-related activities in 14 domains using
a self-administered daily time management log.
Substudy no. 2: PROSPECT capsule quality
We evaluated the content of the probiotic administered,
taking one capsule from every 10 sheets (10 capsules per
sheet) and culturing it in the Surette Laboratory at
McMaster University. The study product was first rolled
over a brain heart infusion agar medium (BD Difco,
Franklin lakes, USA) to determine the presence of mi-
croorganisms on the exterior of the capsule follow by
enumeration by serial dilution of the content of the cap-
sule on de Man, Rogosa and Sharpe (BD Difco, Franklin
lakes, USA) [21] and brain heart infusion agar media at
the appropriate dilution. Subsequently, the numbers of
colony-forming units were counted to determine the
total number of colony-forming units per capsule and to
evaluate whether organisms other than Lactobacillus
were recovered.
Substudy no. 3: serum markers of inflammation and
microbiome feasibility study
From mechanically ventilated patients enrolled in PRO-
SPECT in three centers in Hamilton, ON, local research
coordinators obtained specimens on the day of enroll-
ment, then each Monday, Wednesday and Friday during
the patient’s ICU stay for the first 30 days, then Tuesday
and Thursday thereafter for a maximum of 60 days.
Specimens were procured, packaged in biohazard-safe
material, and couriered via the interhospital within-city
specimen transport system to the Surette and Bowdish
Laboratories at McMaster University. We analyzed
serum endotoxin activity assay and cytokine levels in
blood, and microorganisms identified by culture-
independent techniques in endotracheal aspirates, bron-
chial washings, gastric aspirates, and stool.
Analysis
Baseline characteristics were presented by Group A versus
Group B to evaluate the success of the randomization and
reported as count (percentage) for categorical variables
and mean (standard deviation) or median (first quartile
to third quartile) for continuous variables depending on
the distribution. Analyses of feasibility outcomes were
made on the full cohort of 150 patients rather than ac-
cording to the two randomized groups to retain the
blinding; thus, no comparison between groups was
needed to analyze feasibility outcomes. The feasibility
outcomes were analyzed using descriptive statistics as
follows: (1) mean (standard deviation) number re-
cruited across all recruiting centers per month; (2)
overall proportion of doses received divided by total
doses prescribed; (3) total number of patients who ever
received open-label probiotics as a proportion of all
randomized patients; and (4) the proportion of patients
who developed VAP according to the Centers for Dis-
ease Control and Prevention definition [13] in a sub-
group of 99 patients as assessed by five adjudicators,
with disagreements settled by consensus.
No interim analyses or subgroup analyses were
planned, owing to the short duration and sample size of
this pilot trial. All analysis was performed using SAS ver-
sion 9.2.
Sample size estimation
Our approach to sample size for the PROSPECT pilot
trial was focused on feasibility. Thus, the sample size
was based on interpreting the lower bound of confidence
intervals around estimates [22], which in this case was
around the feasibility objective of adherence to protocol,
whereby successful adherence is defined as ≥80 % of pre-
scribed intervention being administered. Using each
patient as the unit of analysis, rather than doses pre-
scribed, the PROSPECT pilot trial sample size calcula-
tion would have claimed feasibility if at least 80 % of the
patients achieved successful protocol adherence. Assum-
ing a preliminary estimate of 0.85, and a margin of error
of 0.05, recruiting 150 patients will give a 95 % confi-
dence interval estimate of the proportion of patients
with successful protocol adherence with a lower bound
of 0.80 [12].
Management
To ensure protocol adherence and data quality, training
sessions were held for research personnel at all sites
using procedure manuals, standard operating proce-
dures, slide presentations, and a study website. The
PROSPECT steering committee was responsible for the
conduct of this pilot trial, for upholding or modifying
study procedures as needed, addressing challenges with
protocol implementation, refining the protocol as
needed, and reviewing the data.
The PROSPECT pilot trial was managed by McMaster
University’s CLARITY research group, and was con-
ducted under the auspices of the Canadian Critical Care
Trials group [23, 24].
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Results
Setting
The PROSPECT pilot trial was conducted between Oc-
tober 2013 and August 2014 in 14 ICUs: eight in On-
tario [St. Joseph Healthcare, Hamilton; Hamilton Health
Sciences, Hamilton (two ICUs), St. Michael’s Hospital,
Toronto; Mount Sinai Hospital; Ottawa Health Research
Institute (two ICUs); and the University Health Net-
work—Toronto General Hospital]; one in Quebec [CHU
de Québec-Université Laval; Hôpital de l’Enfant-Jésus
site]; three in British Columbia [St Paul’s Hospital; Van-
couver General; and the Royal Jubilee Hospital, Vancou-
ver Island]; and two in the USA (Mayo Clinic, Rochester,
MN and the St. John’s Mercy Hospital, St. Louis, MO).
Enrollment
We enrolled 150 patients. The most common reason for
non-enrollment of eligible patients was lack of availabil-
ity of a substitute decision maker (65 situations, 51.6 %;
Table 1). The consent rate for substitute decision makers
or patients who were approached was 150/180 (83.3 %).
Enrolled patients were 60.0 (16.3) years of age [mean
(standard deviation)], had an APACHE II score of 21.8
(7.9), and 62 (41.3 %) were female (Table 2). Patients
had mostly medical (126, 84.0 %), but also surgical (8,
5.3 %), or trauma (16, 10.7 %) admitting diagnoses. At
baseline, 84 (56.0 %) patients were receiving inotropes or
vasopressors and 18 (12.0 %) were receiving dialysis.
Baseline characteristics were comparable between Group
A (N = 78 patients) and Group B (N = 72 patients).
Feasibility outcomes
The results of the four feasibility outcomes were as fol-
lows: (1) the recruitment rate was 1.9 patients/center/
month; (2) of 2107 patient-days in the ICU, a missed
dose occurred in only 54 (2.6 %) of cases. Therefore,
97.4 % of the prescribed study product was administered
as scheduled; (3) no enrolled patient received open-label
probiotic after randomization; and (4) the adjudicated
VAP rate was 19.2 %.
Clinical outcomes
Table 3 summarizes all non-VAP infections that oc-
curred in these patients after randomization. Blood-
stream infections were the most common infection
(19.3 %), followed by urinary tract infections (12.7 %)
and skin and soft tissue infections (4.0 %).
Patients had 1 (0–3) [median (interquartile range)]
stools/day. Diarrhea defined as Bristol type 6 or 7 stools
occurred in 133 (88.7 %) of patients, reflecting 56.6 %
patient-days in ICU. Diarrhea defined as ≥3 stools/day
occurred in 110 (73.3 %) patients, reflecting 555 (26.5 %)
of patient-days. Antibiotic-associated diarrhea occurred
in 95 (63.3 %) patients using the ≥3 stools/day definition.
Overall, 56 (37.3 %) of patients used a fecal management
device (rectal bag or tube) during their ICU stay, on
average 4.5 days after admission. A fecal management
device was used for 465 (22.1 %) of 2101 patient-days in
ICU (missing stools data for 6 days).
Clostridium difficile infection occurred in two patients
before ICU admission and before trial enrollment.
Thereafter, two (1.3 %) patients developed this infection
in the ICU and five (3.3 %) patients developed it after
ICU discharge.
Duration of mechanical ventilation, ICU and hospital stay,
and mortality
The median (quartile 1 to quartile 3) duration of mech-
anical ventilation was 7 (3–14) days. The median dur-
ation of stay in ICU was 12 (7–18) days, and in hospital
was 26 (14–44) days. There were 23/150 (15.3 %) ICU
and 39/150 (26.0 %) hospital deaths. No patients were
lost to follow-up.
Antimicrobial administration
Antibiotic therapy was administered to 139 (92.7 %) pa-
tients, for 1333 (63.3 %) of 2107 patient-days in the ICU,
for a duration of 7 (quartile 1 to quartile 3, 3–12) me-
dian days (Table 4). There were 660.7 days of antibiotic
or antifungal therapy per 1000 ICU patient-days. There
were 339.3 antimicrobial-free days per 1000 ICU
patient-days.
Serious adverse events
One immunocompetent patient had Lactobacillus spe-
cies identified in a blood culture drawn from an arterial
catheter after 4 days in the trial; the concurrent central
venous catheter blood culture was negative. Although
this patient remained asymptomatic, both catheters were




No substitute decision maker available 65 (51.6)
Patient or substitute decision maker declined 30 (23.8)
Missed 13 (10.3)
Coenrollment not pursued 7 (5.6)
Coenrollment prohibited 3 (2.4)
Language barrier 3 (2.4)
Physician decline (family stress) 2 (1.6)
Research coordinator did not approach
(family stress)
1 (0.8)
Industry prohibited coenrollment 1 (0.8)
International visitor 1 (0.8)
Unknown reason 0 (0.0)
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removed and the patient was treated with ciprofloxacin
for 10 days. As this was not classified as a serious ad-
verse event [19], we did not unblind this patient’s alloca-
tion. It was unclear whether this represented an
endogenous L. rhamnosus isolate that translocated from
the gut, whether this was probiotic that translocated
from the gut, or whether there had been contamination
with probiotic to the hands of the person breaking the
capsule then attending to the arterial catheter. This was
classified as an adverse event [19, 25]. There were no
serious adverse events in the PROSPECT pilot trial.
Substudy no. 1: PROSPECT-TIMES
In seven participating centers, 62 patients were enrolled,
taking an average of 9.2 hours of work per patient (range
3.2–28.5 hours/patient). Study day 1 activities (screen-
ing, consenting, and enrolling) took significantly longer
than subsequent days in the trial (2.1 [standard devi-
ation, 1.1] hours versus 0.76 [standard deviation, 0.71]
hours, respectively [P < 0.01]) (Fig. 2) [26] and tended to
spend fewer hours on each enrolled patient as the trial
unfolded. On an average study day, research coordina-
tors spent 0.9 (standard deviation, 0.8) hours per en-
rolled patient. Primary activities included data collection
(55 %), ICU team communication (10 %), obtaining con-
sent (6 %), responding to queries (6 %), and bedside
charting (5 %).
Substudy no. 2: PROSPECT capsule quality
We tested 34 probiotic capsules from 10 centers and
used a process bar-chart to monitor the number of
colony-forming units of L. rhamnosus GG (on a logarith-
mic scale) over 25 months. Each probiotic capsule
contained at least 1010 colony-forming units of L. rham-
nosus GG (10 on a logarithmic scale). The bacterial con-
tent of the capsules remained above the established
threshold of 1010 colony-forming units and controlled
within three standard deviations on the logarithmic scale
for up to 25 months (Fig. 3).
Table 2 Baseline characteristics of randomized patients (150 patients, divided into Groups A and B, to maintain blinding)
Group A Group B Total
N = 78 N = 72 N = 150
Age (years), mean (standard deviation) 58.8 (17.0) 61.2 (15.4) 60.0 (16.3)
APACHE II, mean (standard deviation) 21.0 (8.4) 22.7 (7.3) 21.8 (7.9)
Female, n (%) 31 (39.7) 31 (43.1) 62 (41.3)
Type of patient, n (%)
Medical 66 (84.6) 60 (83.3) 126 (84.0)
Surgical 3 (3.8) 5 (6.9) 8 (5.3)
Trauma 9 (11.5) 7 (9.7) 16 (10.7)
Admitting diagnosis, n (%)
Cardiovascular 4 (5.1) 4 (5.6) 8 (5.3)
Respiratory 35 (44.9) 26 (36.1) 61 (40.7)
Gastrointestinal 2 (2.6) 0 (0.0) 2 (1.3)
Neurologic 8 (10.3) 10 (13.9) 18 (12.0)
Sepsis 16 (20.5) 17 (23.6) 33 (22.0)
Trauma 7 (9.0) 7 (9.7) 14 (9.3)
Metabolic 2 (2.6) 1 (1.4) 3 (2.0)
Hematologic 1 (1.3) 0 (0.0) 1 (0.7)
Renal 1 (1.3) 2 (2.8) 3 (2.0)
Other medical 2 (2.6) 4 (5.6) 6 (4.0)
Other surgical 0 (0.0) 1 (1.4) 1 (0.7)
Table 3 Secondary clinical outcomes in 150 patients after
randomization
Source, n (%) Following randomization: total
N = 150
Blood culture positive 29 (19.3)
Intra-abdominal infection 5 (3.3)
Urinary culture positive 19 (12.7)
Skin or soft tissue infection 6 (4.0)
Lactobacillus species cultured from
sterile site
1 (0.7)
Diarrhea (≥3 stools/day) 110 (73.3)
Antibiotic-associated diarrhea 95 (63.3)
Clostridium difficile infection 2 (1.3)
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Substudy no. 3: Serum markers of inflammation and
microbiome feasibility study
Overall, 938 samples were procured from 42 patients in
three ICUs; 909 of these (96.9 %) were processed. Of the
29 specimens not processed, the reasons were: receipt
beyond the 3 hour time frame for valid analysis (n = 10
specimens), no kits available (n = 7), no transportation due
to holiday or inclement weather (n = 4), no laboratory staff
due to conference (n = 4), lost in transport (n = 2), insuffi-
cient quantity (n = 1), and missed (n = 1).
We estimated on average that each specimen required
5 min to procure, package, and ship (shipping and pro-
cessing times were not estimated). Also, for each day
that any specimens were transported, we estimated
5 min to communicate with the laboratory and docu-
ment specimens on the study log, and 10 min to make a
return trip with the specimens from the ICU to the
transportation office, for every two patients with speci-
mens collected on that day. Sending specimens to the
central laboratory took ICU research coordinators a
mean of 58.2 (standard deviation, 31.7) min (total range,
20–180) per specimen collection day per site. For 42 pa-
tients, 122.2 total hours were spent on specimen pro-
curement, packaging, and shipping.
Discussion
We designed the PROSPECT pilot trial with four spe-
cific feasibility objectives in preparation for a future lar-
ger multicenter trial comparing probiotics with placebo.
This pilot trial achieved prespecified feasibility objectives
in four domains: (1) recruitment was 1.9 patients per
month among actively recruiting centers—a total of 150
patients were randomized over 1 year, (2) protocol
Table 4 Antimicrobial administration for 150 patients over 2107
patient-days in the ICU





Antibiotic or antifungal 1392 (66.1)
Any antimicrobial (antibiotic or antifungal or
antiviral)
1397 (66.3)
Antimicrobial (antibiotic or antifungal) free days 715 (33.9)
Ever in ICU up to day 60, n (%) N = 150 patients
Antibiotic received 139 (92.7)
Antifungal received 14 (9.3)
Antiviral received 12 (8.0)
Antibiotic or antifungal received 139 (92.7)
Any antimicrobial (antibiotic or antifungal or
antiviral) received
140 (93.3)
No antibiotic or antifungal ever received 11 (7.3)
Days of antimicrobial receipt, median (quartile 1
to quartile 3)
N = 139 patients
Only in patients who received the antimicrobial
Days on antibiotic 7 (3–12)
Days on antifungal 10.5 (5–19)
Days on antiviral 2 (1.5–5)
Days on antibiotic or antifungal 8 (3–13)


































Fig. 2 Average number of hours spent by the PROSPECT pilot trial
research coordinator screening, obtaining consent, and enrolling
patients per study day of the trial.
Fig. 3 Capsule quality assurance results. The quality control protocol
was performed on 34 probiotic capsules used in the PROSPECT
pilot trial
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adherence was high—97 % of doses prescribed were ac-
tually received, (3) contamination with open-label pro-
biotics did not occur, and (4) the VAP rate was 19 %. In
this cohort, many patients had nosocomial infections,
and most were prescribed antimicrobials and developed
diarrhea. No enrolled patients were lost to follow-up.
We found that this pilot trial was a worthwhile invest-
ment and that its completion will serve to enhance re-
search efficiency. This pilot trial will maximize the
chance that the future main trial is designed rigorously,
conducted safely and efficiently, and completed as
planned [22, 27]. Other strengths of this study include
concealed allocation, and blinding of all possible parties
(patient, family, bedside clinicians, research personnel,
and biostatistician) which helped to avoid unequal co-
interventions, ascertainment bias, outcome modification,
and analytic bias.
The three PROSPECT substudies were also inform-
ative. We documented that research staff spent an aver-
age of 1 hour per day on enrolled patients, which is
useful for personnel and budgetary planning. Additional
specimen collection for a mechanistic substudy on
serum markers of inflammation and the microbiome
took 1 hour per day. The quality assurance substudy
yielded reassuring results in that the bacterial content of
probiotic capsules tested remained above the protocol
threshold of 1010 colony-forming units of L. rhamnosus
GG up to 2 years after the manufacturing date; however,
we plan to continue performing quality control micro-
biological analysis, evaluating one capsule from every
tenth capsule sheet (1 %) during the main trial.
Limitations of this study include the modest sample
size to address clinical outcomes, although enough pa-
tients were enrolled to address our feasibility objectives.
Accordingly, no significance testing between groups was
needed for analysis to evaluate the feasibility objectives,
thereby retaining the blinding. The estimated 19 % inci-
dence of VAP was based on a sample of two-thirds of
enrolled patients, not the entire cohort, as our fourth
feasibility objective was only to ensure that the rate was
at least 10 %.
The PROSPECT pilot trial will be an internal pilot trial
[27], and patients will be rolled into the main PRO-
SPECT trial. Indeed, beyond the pilot trial, we launched
the PROSPECT vanguard phase to avoid complete study
cessation and a hiatus between the pilot trial completion
and the main PROSPECT trial start-up. That is, after the
PROSPECT pilot trial enrollment ended at 150 patients,
we analyzed the pilot trial results, and continued to
enrol 250 patients. We are now poised to launch the
main PROSPECT trial.
The clinical and economic burden of VAP remains
high [8] and the use of existing VAP prevention strat-
egies is variable but disappointing in Canada [28]; thus,
a simple, inexpensive, and safe prevention strategy could
further reduce VAP rates. VAP continues to be a key
‘quality indicator’ for most hospitals in Canada (http://
www.patientsafetyinstitute.ca/en/About/Programs/SHN/
Pages/default.aspx), and is emphasized by the Institute
for Healthcare Improvement (http://www.ihi.org/Pages/
default.aspx), which motivates identification of inexpen-
sive strategies to prevent VAP that can be successfully
implemented and that do not involve antibiotics, given
the worldwide resistance problem [29]. Recently, a Mar-
kov cost–benefit decision model determined that, from
the hospital perspective, the VAP prevention strategy
with the optimal cost–benefit ratio included probiotics,
a suction endotracheal tube, and the revised Institute for
Healthcare Improvement bundle, which excludes oral
care [30].
Conclusions
In summary, our results suggest that a large randomized
controlled trial of probiotics in critically ill patients
would be feasible. Probiotics remain a promising method
to prevent VAP and other infections in critically ill pa-
tients, with biologic plausibility, clinical promise, and ap-
parent cost-effectiveness, based on data available to date.
Also, probiotics might have other salutary effects rele-
vant to the antimicrobial stewardship movement, such
as decreased initiation of antimicrobials and decreased
duration of antimicrobial therapy. Probiotics constitute a
promising method to prevent infection in critically ill
patients. The large trial that is required to inform the
overall effects of probiotics on clinical outcomes is now
underway (NCT02462590).
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